Skip to main content
SpringerLink
Log in

Medication Considerations in Hypercalcemia and Hyperparathyroidism

  • Chapter
  • First Online:
Hyperparathyroidism

  • 783 Accesses

Abstract

Hypercalcemia associated with hydrochlorothiazide is a well-known clinical entity, likely due to an increased renal tubular reabsorption of calcium. However, it is estimated that approximately two-thirds of patients with thiazide-associated hypercalcemia have underlying primary hyperparathyroidism (PHPT). Persistence of hypercalcemia after more than 2 years of thiazide use and higher serum calcium and parathyroid hormone (PTH) levels at diagnosis suggest PHPT. Many commonly used medications can also influence calcium and PTH measurement in patients with PHPT, including estrogen, raloxifene, calcium, and vitamin D. A number of other commonly used medications can influence PTH and calcium measurements in patients without PHPT including numerous antihypertensive agents, aromatase inhibitors, estrogen, tenofovir, and several osteoporosis therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wermers RA, Kearns AE, Jenkins GD, Melton 3rd LJ. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med. 2007;120:911 e919–915.

    Article  Google Scholar 

  2. Brickman AS, Massry SG, Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms. J Clin Invest. 1972;51:945–54.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Grieff M, Bushinsky DA. Diuretics and disorders of calcium homeostasis. Semin Nephrol. 2011;31:535–41.

    Article  PubMed  CAS  Google Scholar 

  4. Middler S, Pak CY, Murad F, Bartter FC. Thiazide diuretics and calcium metabolism. Metabolism. 1973;22:139–46.

    Article  PubMed  CAS  Google Scholar 

  5. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women. Eur J Clin Invest. 2001;31:764–72.

    Article  PubMed  CAS  Google Scholar 

  6. Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int. 2007;18:479–86.

    Article  PubMed  CAS  Google Scholar 

  7. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med. 1984;100:633–40.

    Article  PubMed  CAS  Google Scholar 

  8. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174–8.

    Article  PubMed  CAS  Google Scholar 

  9. Tohme JF, Bilezikian JP, Clemens TL, Silverberg SJ, Shane E, Lindsay R. Suppression of parathyroid hormone secretion with oral calcium in normal subjects and patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 1990;70:951–6.

    Article  PubMed  CAS  Google Scholar 

  10. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005;90:2122–6.

    Article  PubMed  CAS  Google Scholar 

  11. Mallette LE, Eichhorn E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med. 1986;146:770–6.

    Article  PubMed  CAS  Google Scholar 

  12. Heshmati HM, Khosla S, Robins SP, O’Fallon WM, Melton 3rd LJ, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res. 2002;17:172–8.

    Article  PubMed  CAS  Google Scholar 

  13. Khosla S, Melton 3rd LJ, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26:441–51.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1–9.

    Article  PubMed  CAS  Google Scholar 

  15. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66.

    Article  PubMed  CAS  Google Scholar 

  16. Adami S, Mian M, Bertoldo F, et al. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol. 1990;33:391–7.

    Article  CAS  Google Scholar 

  17. Generali D, Dovio A, Tampellini M, et al. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer. 2008;98:1753–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Greenspan SL, Holland S, Maitland-Ramsey L, et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians. 1996;108:230–8.

    PubMed  CAS  Google Scholar 

  19. Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporosis Int. 2008;19:1055–65.

    Article  CAS  Google Scholar 

  20. Krege JH, Donley DW, Marcus R. Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med. 2005;353:634–5; author reply 634–5.

    Article  PubMed  CAS  Google Scholar 

  21. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41–50.

    Article  PubMed  CAS  Google Scholar 

  22. Brown J, de Boer IH, Robinson-Cohen C, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100:490–9.

    Article  PubMed  CAS  Google Scholar 

  23. Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation. Ann Intern Med. 2015;162:815–24.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of Interest

All authors state that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo College of Medicine, Mayo Clinic, Rochester, MN, USA

    Robert A. Wermers MD

  2. Department of Internal Medicine, Sanford University of South Dakota Medical Center, Sioux Falls, SD, USA

    Marcio L. Griebeler MD

Authors
  1. Robert A. Wermers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcio L. Griebeler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Wermers MD .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Rochester, Minnesota, USA

    Ann E. Kearns

  2. Mayo Clinic, Rochester, Minnesota, USA

    Robert A. Wermers

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Wermers, R.A., Griebeler, M.L. (2016). Medication Considerations in Hypercalcemia and Hyperparathyroidism. In: Kearns, A., Wermers, R. (eds) Hyperparathyroidism. Springer, Cham. https://doi.org/10.1007/978-3-319-25880-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-25880-5_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-25878-2

  • Online ISBN: 978-3-319-25880-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation